<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802515</url>
  </required_header>
  <id_info>
    <org_study_id>1206010407</org_study_id>
    <nct_id>NCT01802515</nct_id>
  </id_info>
  <brief_title>A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment</brief_title>
  <official_title>Atomoxetine Treatment for Opioid Maintained Cocaine Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to evaluate the safety and tolerability of 40 or 80 mg
      atomoxetine as a treatment for cocaine dependence. The Phase I studies summarized above
      support the safety of atomoxetine in combination with stimulants. As the next step, the
      investigators will evaluate the safety and tolerability of atomoxetine in a small clinical
      trial with cocaine users. If atomoxetine is found to be promising in this study and
      sufficiently powered, double-blind, placebo-controlled studies will be proposed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an approximately 13 to 14 week double-blind, placebo-controlled clinical trial
      testing the safety and feasibility of atomoxetine (40 or 80 mg/day) treatment, compared to
      placebo, in methadone-stabilized stimulant users. The study will have 3 phases: 1) a one to
      two week- methadone-induction phase; 2) an 8-week &quot;treatment&quot; phase; and 3) 1 week
      atomoxetine taper and about a 4-week methadone &quot;taper and detoxification or transfer&quot; phase.
      Subjects will be randomized to three treatment arms: 40 mg (n=15) atomoxetine, or 80 mg
      (n=15) atomoxetine, or placebo (n=15). During the methadone induction phase, subjects will be
      stabilized on methadone. During induction onto methadone, participants will be administered
      increasing doses of methadone starting at 30 mg daily, and this dose will be increased for
      stabilization of opiate withdrawal symptoms from 40 mg up to 140 mg depending on individual
      need. Based on the clinic schedule between 1 to 2 weeks after methadone treatment is
      initiated , atomoxetine treatment will be started at 40 mg/day. For those assigned to 80 mg
      of atomoxetine, the dose will be titrated up to 80 mg/day on the second week of treatment
      phase. At the end of the treatment-phase, subjects will undergo detoxification from methadone
      over a 4-week period based on an individual's needs, and they will concurrently be tapered
      off atomoxetine. All participants will receive a weekly one-hour of individual psychotherapy
      (Cognitive Behavioral Therapy) with experienced clinicians specifically trained to deliver
      the therapy, and who will receive ongoing supervision.

      This study has been terminated as of march 2014 due to the lack of funding, only 14 were
      enrolled with 11 subject completers. (June 2016)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No funding stopped recruitment march 2014 with only 14 enrolled
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Retention</measure>
    <time_frame>8 weeks of treatment</time_frame>
    <description>The number of participants completing all 8 weeks of treatment phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Score in the Center for Epidemiological Studies-Depression (CES-D) Scale</measure>
    <time_frame>8 weeks of treatment</time_frame>
    <description>Center for Epidemiological Studies-Depression. The CES-D is a 20-item self-report measure of depressive symptoms. Each of the 20 items can yield a score from 0 to 3 for a maximum total CES-D score of 60. Larger values represent more severe symptoms. It is a validated instrument with a score of 16 or more indicating clinically significant depression. The CES-D change score was computed as (total baseline CES-D score - total CES-D score at end of study).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>Atomoxetine, low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine, high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine, low dose</intervention_name>
    <description>The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.</description>
    <arm_group_label>Atomoxetine, low dose</arm_group_label>
    <other_name>Strattera,</other_name>
    <other_name>National Drug Codes - 00002-3229</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine, high dose</intervention_name>
    <description>The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.</description>
    <arm_group_label>Atomoxetine, high dose</arm_group_label>
    <other_name>Strattera, National Drug Codes - 00002-3250</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.</description>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Men and women between 18 and 65 years old.

               -  Current opioid dependence as evidenced by 1) documentation of prior treatment for
                  opioid dependence or signs of withdrawal, 2) self-reported history of opioid
                  dependence for 12 consecutive months and, 3) a positive urine toxicology screen
                  for opiates.

               -  Diagnosis of opioid dependence and cocaine dependence by Diagnostic and
                  Statisical Manual (DSM-IV) -criteria as well as laboratory confirmation of recent
                  cocaine use in the form of positive urine toxicology during the month prior to
                  study entry.

               -  For those who recently participated in a research study, at least 2 weeks of
                  washout period before enrollment.

               -  A history of cocaine use,( a minimum of 1/2 gram during the preceding 30 days).

               -  Must be seeking treatment for opioid and cocaine use.

               -  For women of childbearing age, a negative pregnancy test at screening with
                  agreement to use adequate contraception to prevent pregnancy and monthly
                  pregnancy tests.

        Exclusion Criteria:

          -  • Serious medical illnesses including hypertension, tachycardia, bradycardia, or other
             arrhythmias and major cardiovascular, cerebrovascular, renal, endocrine, or hepatic
             disorders;

               -  Serious psychiatric illness, history of psychosis, schizophrenia or bipolar type
                  I disorder.

               -  Current major depression. Subjects with current depressive symptoms not meeting
                  criteria will be included in the study, with the exception of those endorsing
                  suicidal and homicidal thoughts, will be excluded even if full criteria for major
                  depression are not met.

               -  Current diagnosis of alcohol or drug dependence other than opiates, cocaine,
                  nicotine and cannabis.

               -  Current use of over-the-counter or prescription psychoactive drugs
                  (antidepressant, anxiolytics, antipsychotics, mood stabilizers, psychostimulants)
                  or drugs that would be expected to have major interactions with drugs to be
                  tested, e.g., benzodiazepines, codeine, percocet, and other opiate drugs that
                  will interact with methadone.

               -  Has not been treated with monoamine oxidase inhibitors within the last fourteen
                  days.

               -  Liver function tests (ALT or AST) greater than 3 times normal.

               -  Known allergy or intolerance to atomoxetine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Veterans Affairs Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <results_first_submitted>July 7, 2016</results_first_submitted>
  <results_first_submitted_qc>October 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2016</results_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>addiction</keyword>
  <keyword>cocaine</keyword>
  <keyword>methadone</keyword>
  <keyword>opiates</keyword>
  <keyword>atomoxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult male and female participants were recruited from the Greater New Haven area from September 2012 to January 2014 by word-of-mouth, flyers and from referrals from treatment centers in the local area. The study was conducted in an outpatient clinic of the West Haven VA Hospital.</recruitment_details>
      <pre_assignment_details>After eligibility was determined, participants were randomized to placebo, 40 mg atomoxetine or 80 mg atomoxetine. The study consisted of 3 phases 1) a two-week methadone induction phase 2) an 8-week treatment phase and 3) a 4-week taper and detoxification or transfer phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atomoxetine, Low Dose</title>
          <description>1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
Atomoxetine, low dose: The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.</description>
        </group>
        <group group_id="P2">
          <title>Atomoxetine, High Dose</title>
          <description>One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
Atomoxetine, high dose: The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Sugar Pill)</title>
          <description>1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
Placebo: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atomoxetine, Low Dose</title>
          <description>1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
Atomoxetine, low dose: The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.</description>
        </group>
        <group group_id="B2">
          <title>Atomoxetine, High Dose</title>
          <description>One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
Atomoxetine, high dose: The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Sugar Pill)</title>
          <description>1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
Placebo: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" spread="8.0"/>
                    <measurement group_id="B2" value="47.6" spread="5.63"/>
                    <measurement group_id="B3" value="43.6" spread="0.95"/>
                    <measurement group_id="B4" value="42.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Retention</title>
        <description>The number of participants completing all 8 weeks of treatment phase.</description>
        <time_frame>8 weeks of treatment</time_frame>
        <population>Descriptive statistics were calculated for all enrolled subjects. A full statistical analysis was not performed due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine, Low Dose</title>
            <description>1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
Atomoxetine, low dose: The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.</description>
          </group>
          <group group_id="O2">
            <title>Atomoxetine, High Dose</title>
            <description>One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
Atomoxetine, high dose: The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sugar Pill)</title>
            <description>1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
Placebo: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Retention</title>
          <description>The number of participants completing all 8 weeks of treatment phase.</description>
          <population>Descriptive statistics were calculated for all enrolled subjects. A full statistical analysis was not performed due to study termination.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Score in the Center for Epidemiological Studies-Depression (CES-D) Scale</title>
        <description>Center for Epidemiological Studies-Depression. The CES-D is a 20-item self-report measure of depressive symptoms. Each of the 20 items can yield a score from 0 to 3 for a maximum total CES-D score of 60. Larger values represent more severe symptoms. It is a validated instrument with a score of 16 or more indicating clinically significant depression. The CES-D change score was computed as (total baseline CES-D score - total CES-D score at end of study).</description>
        <time_frame>8 weeks of treatment</time_frame>
        <population>Descriptive statistics were calculated for all enrolled subjects. A full statistical analysis was not performed due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine, Low Dose</title>
            <description>1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
Atomoxetine, low dose: The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.</description>
          </group>
          <group group_id="O2">
            <title>Atomoxetine, High Dose</title>
            <description>One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
Atomoxetine, high dose: The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sugar Pill)</title>
            <description>1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
Placebo: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Score in the Center for Epidemiological Studies-Depression (CES-D) Scale</title>
          <description>Center for Epidemiological Studies-Depression. The CES-D is a 20-item self-report measure of depressive symptoms. Each of the 20 items can yield a score from 0 to 3 for a maximum total CES-D score of 60. Larger values represent more severe symptoms. It is a validated instrument with a score of 16 or more indicating clinically significant depression. The CES-D change score was computed as (total baseline CES-D score - total CES-D score at end of study).</description>
          <population>Descriptive statistics were calculated for all enrolled subjects. A full statistical analysis was not performed due to study termination.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="5.2"/>
                    <measurement group_id="O2" value="-2.2" spread="9.1"/>
                    <measurement group_id="O3" value="-3.3" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected once per week on all enrolled subjects for the 8 weeks of the treatment phase.</time_frame>
      <desc>The assessment of adverse events utilized the Brief Symptom Inventory (BSI), an instrument that consists of 77 items.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atomoxetine, Low Dose</title>
          <description>1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
Atomoxetine, low dose: The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.</description>
        </group>
        <group group_id="E2">
          <title>Atomoxetine, High Dose</title>
          <description>One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
Atomoxetine, high dose: The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Sugar Pill)</title>
          <description>1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
Placebo: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>yawning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>tiredness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>decreased libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>increased perspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>nightmares</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>numbness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>decreased concentration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>hallucinations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>cramps</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated after 14 subjects enrolled. 11 completers. 3 subjects dropped out in treatment week 7. There were no serious adverse events. Only descriptive statistics were computed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mehmet Sofuoglu, Principal Investigator</name_or_title>
      <organization>Yale University</organization>
      <phone>203 937-4809</phone>
      <email>mehmet.sofuoglu@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

